Guggenheim downgraded Exelixis (EXEL) to Neutral from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- EXEL Earnings this Week: How Will it Perform?
- Exelixis’s Strategic Positioning and Market Prospects Justify Buy Rating Amid RCC Treatment Dynamics
- Buy Rating Affirmed for Exelixis: Promising Phase 3 Trial Results and Favorable Valuation Despite Safety Concerns
- Apple, MARA, Exelixis, Strategy, Dell: Trending by Analysts
- Midday Fly By: GM, Coca-Cola report Q3 beats